Elamipretide TFA is primarily used in research and clinical settings to target mitochondrial dysfunction, which is implicated in various diseases. It is being studied for its potential therapeutic effects in conditions such as Barth syndrome, a rare genetic disorder affecting mitochondrial function. Additionally, it shows promise in addressing heart failure and other cardiovascular diseases by improving mitochondrial efficiency and reducing oxidative stress. Research is also exploring its application in neurodegenerative disorders like Parkinson’s and Alzheimer’s diseases, where mitochondrial dysfunction plays a critical role. Its ability to stabilize mitochondrial membranes and enhance energy production makes it a valuable candidate for treating conditions linked to cellular energy deficits.